Page 20 - 12_2019

González-Vázquez MD, Rafael-Marques MS, Marques-de Sousa S, Duarte MA, Coelho AD.
No existen fármacos inocentes: daño hepatocelular inducido por desloratadina

En nuestra paciente, la suspensión del fármaco y el cambio por alternativa 4. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I.
terapéutica con diferente vía de metabolismo fue fundamental para la rápi- A novel method based on the conclusions of international consensus
da mejoría y la buena evolución. meetings: application to drug-induced liver injuries. J Clin Epidemiol.
1993; 46(11): 1323-1330.
5. Website: LiverTox.nih.gov. Database Updated: 01 November 2018. Accesi-
Bibliografía ble en: https://livertox.nlm.nih.gov/loratadine_Desloratadine.htm
6. Schiano TD, Bellary SV, Cassidy MJ, Thomas RM, Black M. Subfulminant li-
1. Andrade RJ, Lucena MI, Fernández MC, Peláez G, Pachkoria K, García-Ruiz ver failure and severe hepatotoxicity caused by loratadine use. Ann Intern
E, et al. Spanish Group for the Study of Drug-Induced Liver Disease. Drug- Med. 1996; 125(9): 738-740.
induced liver injury: an analysis of 461 incidences submitted to the Spa- 7. Schöttker B, Dösch A, Kraemer DM. Severe hepatotoxicity after applica-
nish registry over a 10-year period. Gastroenterology. 2005; 129(2): 512- tion of desloratadine and fluconazole. Acta Haematol. 2003; 110(1): 43-44.
521. doi: 10.1016/j.gastro.2005.05.006. doi: 10.1159/000072415.
2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. 8. Pérez R, Rodrigo L, Pérez R, de Francisco R. Acute cholestasis related
A method for estimating the probability of adverse drug reactions. Clin to desloratidine. World J Gastroenterol. 2005; 11(23): 3647-3648. doi:
Pharmacol Ther. 1981; 30(2): 239-245. doi: 10.1038/clpt.1981.154. 10.3748/wjg.v11.i23.3647.
3. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the
update. Int J Mol Sci. 2015; 17(1): E14. doi: 10.3390/ijms17010014.

114 Rev Esp Casos Clin Med Intern (RECCMI). 2019 (Dic); 4(3): 111-114